Supplemental Financial Information (Tables)

3 Months Ended

Mar. 31, 2026

Other Balance Sheet Details [Abstract]

Inventory consisted of the following:


(in millions)	March 31, 2026		December 31, 2025
Raw materials	$	30.7	$	35.7
Work in process	21.1		19.2
Finished goods	12.9		14.3
	64.7		69.2
Less inventory reserves	(0.2)		(0.2)
Total inventory	$	64.5	$	69.0

Schedule of Prepaid expenses

Prepaid expenses consisted of the following:


(in millions)	March 31, 2026		December 31, 2025
Prepaid income taxes	$	127.7	$	94.0
Prepaid development costs	69.6		55.6
Other prepaid expenses	27.5		21.1
Total prepaid expenses	$	224.8	$	170.7

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following:


(in millions)	March 31, 2026		December 31, 2025
Sales rebates and reserves	$	231.3	$	226.0
Current income taxes payable	186.4		68.0
Accrued development costs	110.7		101.3
Accrued employee related costs	81.7		128.8
Current branded prescription drug fee	42.9		45.3
Accounts payable and other accrued liabilities	120.0		104.9
Total accounts payable and accrued liabilities	$	773.0	$	674.3

Schedule of Other Noncurrent Liabilities

Other noncurrent liabilities consisted of the following:


(in millions)	March 31, 2026		December 31, 2025
Noncurrent income taxes payable	$	241.3	$	214.5
Other noncurrent liabilities	19.6		5.2
Total other noncurrent liabilities	$	260.9	$	219.7

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.


(in millions)	March 31, 2026		March 31, 2025
Cash and cash equivalents	$	266.5	$	194.1
Restricted cash included in other noncurrent assets	8.0		8.0
Total cash, cash equivalents, and restricted cash	$	274.5	$	202.1